U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks

By Caroline Humer (Reuters) - (Story refiles to correct typographical error in first paragraph to Sovaldi instead of Solvadi) U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, and the company said the drug would cost $83,319 for a typical 12-week plan, a bit below its huge selling competitor Sovaldi from Gilead Sciences. Gilead's Sovaldi treatment stole headlines last year with its $84,000 price tag and set off a national debate about whether drug prices have climbed too high. ...



via Health News Headlines - Yahoo News http://ift.tt/1sQTuIb